

company announcement

Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2014

Bagsværd, Denmark, 30 April 2014 – In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.

Referring to Company Announcement no 25/2014 dated 23 April 2014, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 30 April 2014.

	Number of shares (nominal value DKK 0.20)	Nominal value (DKK)	Number of votes
A shares	537,436,000	107,487,200	107,487,200,000
B shares	2,112,564,000	422,512,800	42,251,280,000

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 514 8316	kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen	+45 3079 4303	krop@novonordisk.com
Frank Daniel Mersebach	+45 3079 0604	fdni@novonordisk.com
Lars Borup Jacobsen	+45 3075 3479	lbpj@novonordisk.com
Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
Jannick Lindegaard (US)	+1 609 235 8567	jlis@novonordisk.com